CoChat

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Our understanding is limited concerning the tumor immune microenvironment of inflammatory breast cancer (IBC), an aggressive form of primary cancer with low rates of pathologic complete response to current neoadjuvant chemotherapy (NAC) regimens. We retrospectively identified pretreatment (N = 86) and matched posttreatment tissue (N = 27) from patients with stage III or de novo stage IV IBC who received NAC followed by a mastectomy. Immune profiling was performed including quantification of lymphoid and myeloid infiltrates by IHC and T-cell repertoire analysis. Thirty-four of 86 cases in this cohort (39.5%) achieved a pathologic complete response. Characterization of the tumor microenvironment revealed that having a lower pretreatment mast cell density was significantly associated with achieving a pathologic complete response to NAC (P = 0.004), with responders also having more stromal tumor-infiltrating lymphocytes (P = 0.035), CD8+ T cells (P = 0.047), and CD20+ B cells (P = 0.054). Spatial analysis showed close proximity of mast cells to CD8+ T cells, CD163+ monocytes/macrophages, and tumor cells when pathologic complete response was not achieved. PD-L1 positivity on tumor cells was found in fewer than 2% of cases and on immune cells in 27% of cases, but with no correlation to response. Our results highlight the strong association of mast cell infiltration with poor response to NAC, suggesting a mechanism of treatment resistance and a potential therapeutic target in IBC. Proximity of mast cells to immune and tumor cells may suggest immunosuppressive or tumor-promoting interactions of these mast cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0619

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Rugo, Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8–12; San Antonio, TX

Cited by

See all 106

Metadata

Authors
Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., Tsujikawa, T., Coussens, L. M., Wani, K., He, Y., Villareal, L., Wood, A., Rao, A., Woodward, W. A., Ueno, N. T., Krishnamurthy, S., Wargo, J. A., & Mittendorf, E. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Michigan (US)
  • Oregon Health & Science University (US)
  • 11Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas.
  • Brigham and Women's Hospital (US)
Corresponding author
  • Krishnamurthy, Savitri
  • Wargo, Jennifer A.
  • Mittendorf, Elizabeth A.
Venue
Cancer Immunology Research
Published
2019-06-01
Volume
7
Issue
6
Pages
1025-1035
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2942793545
Cited by
106
References
53
Citations by year
2026: 6 · 2025: 14 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 15 · 2020: 15 · 2019: 3
FWCI
4.02
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Breast Cancer Research Foundation Conquer Cancer Foundation
  • Breast Cancer Research Foundation
  • Morgan Welch Inflammatory Breast Cancer ResearchState of Texas Rare and Aggressive Breast Cancer ResearchMD Anderson Cancer Center NCI (CA16672)
  • NIH (T32 CA 009666)
  • Kimberley Clark Foundation
  • CCSG (P30 CA016672)
  • University of Texas MD Anderson Cancer Center
  • CPRIT (RP170719, RP150578)
  • NCI (R01CA214955-01A1)
  • American Cancer Society (RSG-16-005-01)
  • Pink Ribbons Project
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
inflammatory breast cancer, neoadjuvant chemotherapy response, mast cell infiltration, tumor immune microenvironment, pathological complete response, tumor-infiltrating lymphocytes, CD8+ T cells, CD20+ B cells, CD163+ macrophages, PD-L1, treatment resistance, spatial analysis
MeSH terms
Adult, Aged, Histocompatibility Antigens Class II, Female, Humans, Macrophages, Mast Cells, Middle Aged, Neoplasm Staging, Prognosis, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Young Adult, Inflammatory Breast Neoplasms, Tumor Microenvironment, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0619
The paper
Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., Tsujikawa, T., Coussens, L. M., Wani, K., He, Y., Villareal, L., Wood, A., Rao, A., Woodward, W. A., Ueno, N. T., . . . Mittendorf, E. A. (2019). Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0619

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.